PsychoGenics Announces Drug Discovery Agreement with Cephalon

Tarrytown, NY, November 7, 2007 - PsychoGenics Inc. today announced that it has entered into a drug discovery agreement with Cephalon, Inc. The agreement provides that Cephalon will supply compounds that are prospectively suitable for neuropsychiatric disorders to PsychoGenics for evaluation using its proprietary drug discovery technologies.Read More.

Translational Research Forum to Explore Philanthropy and Drug Development At 2007 BIO International Convention.

Washington, D.C. ,April 13, 2007 -- Translational research and the individuals who help to support it will be a major highlight of the Sunday programming at the 2007 Biotechnology Industry Organization (BIO) International Convention.Read More.

PsychoGenics Announces the Launch of Psylin Neurosciences, Inc. in Partnership with Amylin Pharmaceuticals

Tarrytown, NY, January 30, 2007 – PsychoGenics Inc. announced today that together with Amylin Pharmaceuticals, Inc. they have formed Psylin Neurosciences, Inc. (Psylin), a new company that will focus on the discovery and development of peptide hormones for treatment of psychiatric disorders. PsychoGenics and Amylin participated equally in a Series A financing of Psylin anticipated to fund the company for approximately the next two years.Read More.

PsychoGenics, together with the Ewing Marion Kauffman Foundation, sponsors the Translational Research Forum at the BIO 2007 International Convention.

The BIO 2007 Translational Research Forum seeks to bring together the major funders of translational research in a full-day program. The speakers and panelists will explore their criteria for selecting and funding programs, as well as describe how pharmaceutical and biotechnology companies and academic centers can be involved in foundation and NIH-driven translational research.Read More.